Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Gorab

Orthopaedic Surgery Orange, CA Medical Doctor

NPI 1326035601 CMS profile 331969

280 S Main St, Ste 200, Orange, CA 92868

Open in the dashboard

General payments

$13,572,448

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$888,725 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Robert Gorab of Orange, CA is reported in the CMS Open Payments database as having received $13,572,448 across 169 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $888,725 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,884,153 12
2024 General $2,525,594 24
2023 General $2,341,301 14
2022 General $2,102,435 21
2021 General $1,896,047 32
2020 General $1,477,763 17
2019 General $1,345,154 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Gorab
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Robert Gorab were reported at $1,884,153. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Robert Gorab Orthopaedic Surgery median Middle half National median
2019 $1,345,154 $644 $140–$2,844 $163
2020 $1,477,763 $312 $75–$1,860 $114
2021 $1,896,047 $520 $117–$2,495 $132
2022 $2,102,435 $598 $128–$2,731 $149
2023 $2,341,301 $461 $128–$2,264 $160
2024 $2,525,594 $497 $134–$2,475 $164
2025 $1,884,153 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Products, Inc. $13,470,403 108 payments
  2. Medical Device Business Services, Inc. $100,712 47 payments
  3. DePuy Synthes Sales Inc. $638 7 payments
  4. Zimmer Biomet Holdings, Inc. $262 2 payments
  5. Smith+Nephew, Inc. $248 2 payments
  6. Pacira Pharmaceuticals Incorporated $126 1 payment
  7. Flexion Therapeutics, Inc. $38 1 payment
  8. Bioventus LLC $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $13,414,409 59 payments
  2. Consulting Fee $147,263 44 payments
  3. Travel and Lodging $8,386 24 payments
  4. Food and Beverage $2,390 42 payments
Products named General payments · program years 2019–2025
  1. ATTUNE Ortho-Knee $10,739,302 72 payments
  2. ACTIS Ortho-Hip $10,668,213 42 payments
  3. ATTUNE Ortho-Knee $2,812,273 63 payments
  4. ACTIS Ortho-Hip $2,751,368 22 payments
  5. SIGMA Ortho-Knee $69,191 25 payments
  6. LCS Ortho-Knee $69,191 25 payments
  7. LCS Ortho-Knee $52,490 17 payments
  8. SIGMA Ortho-Knee $52,490 17 payments
  9. AOX $32,240 14 payments
  10. PINNACLE $10,500 1 payment
  11. Other $17,267 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

498

Median for Orthopaedic Surgery: 30

Drug cost

$3,607

Median for Orthopaedic Surgery: $176

Branded share of claims

8.2%

Median for Orthopaedic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 52 $1,036
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $835
Diclofenac Sodium Generic 83 $681
Meloxicam Generic 179 $534
Oxycodone Hcl Generic 31 $222
Amoxicillin Generic 64 $153
Tramadol Hcl Generic 37 $109
Clindamycin Hcl Generic 11 $37

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,233 Part D prescribers listed as Orthopaedic Surgery; they describe a distribution and say nothing about conduct.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record